6.3 Cardiac, Muscle & Pancreatic Enzymes: CK Isoenzymes, Troponins, Amylase, Lipase, ACE & Cholinesterase

6.3 Cardiac, Muscle & Pancreatic Enzymes: CK Isoenzymes, Troponins, Amylase, Lipase, ACE & Cholinesterase

[!NOTE] Diagnostic Evolution of Organ-Specific Markers: The evaluation of acute coronary syndromes and acute pancreatitis has progressed from non-specific total enzyme catalytic assays (such as total CK and amylase) to high-specificity mass immunoassay biomarkers and organ-restricted enzymes. Modern clinical chemistry relies on High-Sensitivity Cardiac Troponin (hs-cTn) as the definitive cornerstone for myocardial infarction diagnosis, alongside Lipase as the preferred single diagnostic enzyme for acute pancreatitis.

---

Creatine Kinase (CK / CPK)

Creatine Kinase is a cellular kinase that catalyzes the reversible phosphorylation of creatine by adenosine triphosphate (ATP) to form phosphocreatine and adenosine diphosphate (ADP):

$\text{Creatine} + \text{ATP} \xrightleftharpoons{\text{CK, Mg}^{2+}} \text{Phosphocreatine} + \text{ADP}$

• Physiological Role: Phosphocreatine serves as an immediate high-energy phosphate reservoir in tissues with rapid, fluctuating energy demands (skeletal muscle, cardiac myocardium, brain). During intense muscle contraction, CK rapidly regenerates ATP from ADP and phosphocreatine without relying on immediate glycolysis or oxidative phosphorylation.
• Subunit Architecture: CK is a dimeric enzyme (molecular mass ~82 kDa) composed of two polypeptide subunits designated M (Muscle) and B (Brain), encoded by distinct genes on chromosomes 19 and 14.

Analytical Methodology: Oliver-Rosalki Coupled Assay

The standard clinical enzymatic assay operates in the reverse direction (phosphocreatine $\rightarrow$ creatine), which proceeds 2 to 3 times faster than the forward reaction at optimal pH 6.7:

$\text{1. } \text{Phosphocreatine} + \text{ADP} \xrightarrow{\text{CK, Mg}^{2+}} \text{Creatine} + \text{ATP}$ $\text{2. } \text{ATP} + \text{D-Glucose} \xrightarrow{\text{Hexokinase}} \text{Glucose-6-Phosphate (G6P)} + \text{ADP}$ $\text{3. } \text{G6P} + \text{NADP}^+ \xrightarrow{\text{G6PD}} \text{6-Phosphogluconate} + \text{NADPH} + \text{H}^+$

• The rate of reduction of $\text{NADP}^+$ to $\text{NADPH}$ is monitored spectrophotometrically by the increase in absorbance per minute at 340 nm.
• Essential Reagent Additives:
  • Magnesium ($\text{Mg}^{2+}$): Obligate cofactor forming the $[\text{Mg-ADP}]^-$ complex.
  • Thiol Reducing Agents: The catalytic active site of CK contains hyper-reactive cysteine sulfhydryl ($\text{-SH}$) groups that rapidly undergo spontaneous oxidation in stored serum, causing loss of catalytic activity. Reagent formulations incorporate thiol restorers—specifically N-Acetylcysteine (NAC) or dithiothreitol—to reduce disulfides and reactivate oxidized CK.
  • Adenosine Monophosphate (AMP) and Diadenosine Pentaphosphate: Added to inhibit endogenous adenylate kinase (myokinase) released from lysed erythrocytes, which otherwise generates ATP from ADP and produces false-positive CK activity.
• Light Sensitivity: Serum CK is photolabile; exposure to sunlight or fluorescent room light causes rapid photo-oxidation, decreasing activity by up to 10% per hour. Specimens must be stored protected from light.

---

CK Isoenzymes and Atypical Variants

+-----------------------------------------------------------------------------------------+
|                        Creatine Kinase (CK) Isoenzyme Profile                           |
+-----------------------------------------------------------------------------------------+
| Isoenzyme   Subunits  Tissue Distribution          Agarose Electrophoresis Migration    |
+-----------------------------------------------------------------------------------------+
| CK-BB       BB        Brain, Prostate, GI Tract,   Anode (+) ─── [ CK-BB ] (Fastest)    |
| (CK-1)                Bladder, Uterus, Placenta                     │                   |
|                                                                     │                   |
| CK-MB       MB        Myocardium (15-20%),                          [ CK-MB ] (Mid)     |
| (CK-2)                Trace in Skeletal (<1-2%)                     │                   |
|                                                                     │                   |
| CK-MM       MM        Skeletal Muscle (97-99%),    Cathode (-) ── [ CK-MM ] (Slowest)   |
| (CK-3)                Myocardium (70-80%)                                               |
+-----------------------------------------------------------------------------------------+

The Three Cytoplasmic Isoenzymes

1. CK-BB (CK-1):
   • Predominant in brain tissue, gastrointestinal tract, urinary bladder, prostate, and uterus.
   • Electrophoresis: Most negatively charged at pH 8.6; migrates farthest toward the anode (+).
   • Clinical Pathology: Rarely elevated in serum because the blood-brain barrier prevents intact passage into blood. Elevated serum CK-BB indicates extensive blood-brain barrier disruption (anoxic encephalopathy, traumatic brain injury, massive cerebral infarction), bowel infarction, or small cell carcinoma of the prostate/lung.
2. CK-MB (CK-2):
   • Tissue Distribution: Highly enriched in cardiac muscle, where it represents 15% to 20% of total cardiac CK activity (the remaining 80% is CK-MM). In healthy resting skeletal muscle, CK-MB accounts for < 1% to 2% of total CK.
   • Electrophoresis: Exhibits intermediate mobility between CK-BB and CK-MM.
   • Mass Immunoassay: Automated analyzers utilize two-site sandwich immunoassays employing monoclonal antibodies directed against the MB subunit interface to measure mass concentration ($\mu\text{g/L}$) rather than catalytic activity, eliminating interference from atypical variants.
3. CK-MM (CK-3):
   • Predominant isoenzyme in healthy skeletal muscle (97% to 99%) and normal human serum (> 95% of circulating total CK).
   • Electrophoresis: Least negatively charged; migrates closest to the cathode (-).
   • Clinical Pathology: Surges to extreme levels in rhabdomyolysis (crush injury, cocaine intoxication, compartment syndrome), Duchenne Muscular Dystrophy (levels often 20- to 100-fold ULN), polymyositis, severe hypothermia, vigorous exercise (marathon running), and deep intramuscular injections.

The CK-MB Relative Index (RI)

Because skeletal muscle contains trace CK-MB (~1%), massive skeletal muscle trauma (e.g., rhabdomyolysis with total CK = 50,000 U/L) releases enough CK-MB mass to exceed the absolute reference threshold (> 5 $\mu$g/L), creating clinical confusion. The CK-MB Relative Index (RI) resolves this ambiguity by expressing CK-MB mass as a percentage of total CK activity:

$\text{CK-MB Relative Index (RI)} = \left( \frac{\text{CK-MB Mass (}\mu\text{g/L)}}{\text{Total CK Activity (U/L)}} \right) \times 100$

• Diagnostic Interpretation:
  • $\text{RI} > 2.5% \text{ to } 3.0%$: Confirms myocardial origin (acute myocardial infarction, acute myocarditis, cardiac contusion).
  • $\text{RI} < 2.5%$: Indicates skeletal muscle injury; despite an elevated absolute CK-MB mass, the disproportionately massive total CK indicates the primary pathology is rhabdomyolysis or polymyositis.

Atypical CK Variants (Macromolecular Complexes)

When clinical laboratories employ electrophoretic separation or immunoinhibition methods, atypical CK complexes can cause serious analytical artifacts:

• Macro-CK Type 1: A circulating complex of CK-BB (or rarely CK-MM) coupled to an immunoglobulin (most commonly IgG or IgA). It migrates between CK-MB and CK-MM. It is a benign finding seen predominantly in women over 60 years of age, causing unexplained persistent elevation of total CK and false-positive CK-MB activity on immunoinhibition assays.
• Macro-CK Type 2: An oligomeric complex of mitochondrial Creatine Kinase (CK-Mt) released from inner mitochondrial membranes. On electrophoresis, it migrates cathodal to CK-MM (or stays at the application well). It is a pathological marker associated with severe tissue destruction, advanced metastatic malignancy (liver, GI carcinomas), and carries a poor clinical prognosis.

---

Cardiac Biomarkers in Acute Coronary Syndrome (ACS)

+-----------------------------------------------------------------------------------------+
|                    Temporal Release Kinetics of Cardiac Biomarkers                     |
+-----------------------------------------------------------------------------------------+
|  Relative Elevation (x ULN)                                                            |
|       ^                                                                                 |
|       │         /\                                                                      |
|       │        /  \  Myoglobin (Rises 1-3h; Peaks 6-9h; Normal <24h)                    |
|       │       /    \                                                                    |
|       │      /   /\ \                                                                   |
|       │     /   /  \ \   hs-cTnI / hs-cTnT (Rises 3-6h; Peaks 12-24h; Persists 7-14d)   |
|       │    /   /    \ \                                                                 |
|       │   /   /      \ \────────────┐                                                   |
|       │  /   /  /\    \             \                                                   |
|       │ /   /  /  \    \             \                                                  |
|       │/   /  /    \    \             \                                                 |
|       │   /  /  CK-MB \  \             \                                                |
|     0 └──┴──┴──┴───────┴──┴─────────────┴────────────────────────> Time Post-Infarct    |
|          1h 3h 6h     12h 24h           7d          14d                                 |
+-----------------------------------------------------------------------------------------+

Cardiac Troponins (cTnI and cTnT)

• Biochemical Function: Troponin is a heterotrimeric protein complex bound to the actin thin filament of striated muscle myofibrils that regulates calcium-mediated excitation-contraction coupling:
  • Troponin C (TnC): Calcium-binding subunit; identical in cardiac and skeletal muscle.
  • Troponin I (TnI): Inhibitory subunit; prevents actomyosin cross-bridge formation in the absence of calcium.
  • Troponin T (TnT): Tropomyosin-binding subunit; anchors the troponin complex to the actin thin filament.
• Cardiac Specificity: Cardiac isoforms (cTnI and cTnT) possess unique amino acid sequences encoded by distinct cardiac genes ($TNNI3$ and $TNNT2$). They are antigenically distinct from skeletal muscle isoforms, conferring near-absolute tissue specificity.
• Intracellular Pools: Approximately 95% of cardiac troponin is bound to structural myofibrils, while a small pool (3% to 5% of cTnI; 6% to 8% of cTnT) exists freely dissolved in the cytoplasm. Following ischemic necrosis, the cytoplasmic pool leaks first, followed by slow, sustained degradation and release of the structural myofibrillar complex.
• Temporal Kinetics in Acute Myocardial Infarction (AMI):
  • Initial Rise: 3 to 6 hours after the onset of chest pain.
  • Peak Concentration: 12 to 24 hours post-infarction.
  • Duration of Elevation: cTnI remains elevated for 7 to 10 days; cTnT remains elevated for 10 to 14 days.
• Diagnostic Gold Standard: Under the Fourth Universal Definition of Myocardial Infarction, diagnosis requires a dynamic rise and/or fall of cardiac troponin with at least one value exceeding the 99th percentile Upper Reference Limit (URL) of a healthy reference population, accompanied by clinical evidence of acute myocardial ischemia (ECG changes, chest pain, imaging proof).
• High-Sensitivity Troponin (hs-cTn): Automated assays capable of quantifying troponin concentrations at nanogram-per-liter (ng/L) levels with exceptional analytical precision (total analytical coefficient of variation $CV \le 10%$ at the 99th percentile URL). Enables accelerated 0-hour/1-hour and 0-hour/2-hour emergency department rule-out and rule-in diagnostic pathways.
• Non-Thrombotic Causes of Troponin Elevation: While cTn is 100% tissue-specific for the heart, it is not disease-specific for atherothrombotic plaque rupture (Type 1 MI). Elevations occur in secondary myocardial supply-demand mismatch (Type 2 MI), acute pulmonary embolism (right ventricular strain), congestive heart failure, acute myocarditis, sepsis, stroke, and end-stage renal disease (ESRD; impaired renal clearance of fragmented troponin chains, especially cTnT).

Myoglobin

• Biochemical Properties: A small monomeric cytoplasmic heme protein (molecular mass ~17.8 kDa) that stores oxygen in cardiac and skeletal muscle fibers.
• Temporal Kinetics: Because of its small molecular size, myoglobin is rapidly released upon cell membrane disruption. It is the earliest cardiac biomarker to rise, appearing in blood within 1 to 3 hours after onset of myocardial ischemia, peaking at 6 to 9 hours, and rapidly normalizing within 24 to 36 hours via glomerular filtration into urine.
• Clinical Diagnostic Value: Its primary utility lies in its exceptional Negative Predictive Value (NPV). If serum myoglobin remains within normal limits between 2 and 6 hours following acute chest pain, acute myocardial infarction can be excluded with high clinical confidence. However, myoglobin completely lacks cardiac specificity, elevating in skeletal muscle trauma, rhabdomyolysis, intense physical exercise, and renal failure.

Lactate Dehydrogenase (LDH / LD) & The LD Flipped Pattern

• Biochemical Role: A zinc-containing tetrameric enzyme that catalyzes the reversible interconversion of lactate and pyruvate coupled to $\text{NAD}^+ / \text{NADH}$.
• Isoenzyme Subunit Architecture: Formed by the random tetrameric association of two distinct polypeptide subunits: H (Heart) and M (Muscle), yielding five distinct isoenzymes:
  • LD-1 ($H_4$): Predominant in cardiac myocardium and erythrocytes; fastest anodal electrophoretic mobility.
  • LD-2 ($H_3M$): Predominant in the reticuloendothelial system, leukocytes, and normal serum.
  • LD-3 ($H_2M_2$): Predominant in pulmonary tissue, spleen, pancreas, and lymphocytes.
  • LD-4 ($HM_3$): Predominant in kidneys, placenta, and liver.
  • LD-5 ($M_4$): Predominant in skeletal muscle and hepatocytes; slowest cathodal mobility.
• Normal Physiological Pattern: In healthy human serum, electrophoretic activity demonstrates: $\text{LD-2} > \text{LD-1} > \text{LD-3} > \text{LD-4} > \text{LD-5}$.
• The "LD Flipped Pattern" ($\text{LD-1} > \text{LD-2}$):
  • When myocardium undergoes extensive necrosis, massive quantities of LD-1 flood into the circulation, causing serum LD-1 activity to exceed LD-2 ($\text{LD-1}/\text{LD-2} > 1.0$). Historically, this "flipped pattern" was a classic diagnostic hallmark of acute myocardial infarction (rising at 12 to 24 hours, peaking at 48 to 72 hours, and remaining elevated for 10 to 14 days).
  • In Vitro and In Vivo Hemolysis: Because erythrocytes are densely packed with LD-1, intravascular hemolytic anemia, megaloblastic anemia (ineffective erythropoiesis), and in vitro specimen hemolysis produce marked false-positive LD flipped patterns. In modern laboratories, troponins have completely replaced LD for cardiac diagnostics.

---

Pancreatic Enzymes: Amylase & Lipase

+-----------------------------------------------------------------------------------------+
|                   Comparison of Serum Amylase and Lipase in Pancreatitis                |
+-----------------------------------------------------------------------------------------+
| Feature           Serum Amylase (AMS)                   Serum Lipase (LPS)              |
+-----------------------------------------------------------------------------------------+
| Substrate         Hydrolyzes internal α-(1,4)-          Hydrolyzes ester bonds of       |
|                   glucosidic bonds in starch/glycogen   triglycerides at C1 & C3        |
|                                                                                         |
| Cofactors         Calcium (Ca2+, structural) and        Colipase and bile salts         |
|                   Chloride (Cl-, allosteric activator)  (required for full activity)    |
|                                                                                         |
| Primary Tissue    Pancreatic Acinar Cells (P-type) and  Pancreatic Acinar Cells         |
| Distribution      Salivary Glands (S-type)              (Exclusively Pancreas Specific) |
|                                                                                         |
| Molecular Size    Small (~50-55 kDa); Filtered by       Larger (~48-54 kDa); Reabsorbed |
|                   glomerulus into urine                 by renal tubules (no urine LPS) |
|                                                                                         |
| Initial Rise      2 to 12 hours                         4 to 8 hours                    |
| Peak Elevation    24 hours                              24 hours                        |
| Duration / Window Returns to normal in 3 to 5 days      REMAINS ELEVATED 8 TO 14 DAYS   |
|                                                                                         |
| Diagnostic Value  Moderate; confounded by salivary,     SUPERIOR; Preferred single      |
|                   renal, and gynecological pathology    diagnostic test for pancreatitis|
+-----------------------------------------------------------------------------------------+

Amylase ($\alpha$-Amylase / AMS)

• Catalytic Reaction: An endoamylase that hydrolyzes internal $\alpha\text{-(1,4)-glucosidic}$ bonds in complex carbohydrates (starch, glycogen, amylose, amylopectin) to yield maltose, maltotriose, and $\alpha$-dextrins. Cannot cleave $\alpha\text{-(1,6)}$ branch points.
• Cofactors: Requires Calcium ($\text{Ca}^{2+}$) as a tightly bound structural stabilizer and Chloride ($\text{Cl}^-$) or other small monovalent anions as allosteric activators. Inhibited by EDTA, citrate, and oxalate.
• Isoenzymes:
  • S-Type (AMY1): Derived from salivary glands; migrates fastest on electrophoresis. Elevates in mumps, acute suppurative parotitis, salivary calculi, and head/neck trauma.
  • P-Type (AMY2): Synthesized by pancreatic acinar cells. Elevates in acute pancreatitis.
• Renal Clearance and the ACCR:
  • Due to its small molecular mass (~50–55 kDa), serum amylase is freely filtered across the renal glomerular basement membrane into urine. In acute pancreatitis, urinary amylase rises and remains elevated longer (7 to 10 days) than serum amylase.
  • Amylase-to-Creatinine Clearance Ratio (ACCR): Evaluates the renal clearance of amylase relative to glomerular filtration rate: $\text{ACCR (\%)} = \left( \frac{\text{Urine Amylase (U/L)} \times \text{Serum Creatinine (mg/dL)}}{\text{Serum Amylase (U/L)} \times \text{Urine Creatinine (mg/dL)}} \right) \times 100$
  • Normal ACCR: 1% to 4%.
  • Acute Pancreatitis: ACCR typically increases to $> 5%$ due to a transient renal tubular reabsorption defect for amylase.
• Macroamylasemia:
  • A benign, non-pathological condition in which normal amylase molecules form high-molecular-weight circulating complexes with immunoglobulins (predominantly IgA or IgG), creating a macro-complex with a molecular mass exceeding 200 to 400 kDa.
  • The massive macroamylase complex cannot pass through the glomerular filtration barrier.
  • Clinical Presentation: Asymptomatic patient with persistent, chronic elevation of serum total amylase, but with normal or low urinary amylase activity and a characteristically depressed ACCR ($< 1%$).
  • Serum Lipase: Remains completely normal. Recognizing macroamylasemia prevents unnecessary abdominal CT imaging or invasive laparotomy.

Lipase (Triacylglycerol Acylhydrolase / LPS)

• Catalytic Reaction: Hydrolyzes the insoluble ester bonds of emulsified long-chain triglycerides at the 1 and 3 positions, liberating 2-monoglycerides and two free fatty acids: $\text{Triglyceride} + 2\ \text{H}_2\text{O} \xrightarrow[\text{Colipase, Bile Salts}]{\text{Lipase}} \text{2-Monoglyceride} + 2\ \text{Free Fatty Acids}$
• Tissue Specificity: Almost exclusively restricted to pancreatic acinar tissue. While minute quantities of lingual and gastric lipase exist, they do not contribute meaningfully to circulating serum lipase.
• Superiority of Lipase over Amylase:
  1. Greater Tissue Specificity: Lipase is not elevated in salivary disorders, mumps, ovarian malignancy, or ruptured tubal pregnancy.
  2. Extended Diagnostic Window: In acute pancreatitis, lipase rises within 4 to 8 hours, peaks at 24 hours, and remains elevated for 8 to 14 days (compared to amylase, which returns to baseline in 3 to 5 days). This makes lipase the test of choice for patients presenting late after pain onset.
  3. Absence of Macro-Complex Artifacts: Lipase does not form macro-complexes with immunoglobulins; macroamylasemia does not interfere.
  4. Official Guidelines: The American College of Gastroenterology (ACG) and American Pancreatic Association (APA) guidelines state that serum lipase alone is the single preferred diagnostic test for acute pancreatitis; co-ordering amylase provides no added diagnostic value.

---

Additional High-Yield Diagnostic Enzymes

Acid Phosphatase (ACP)

• Hydrolyzes orthophosphoric monoesters at an acid pH (4.8 to 5.2).
• Tissue Distribution: Highly concentrated in the prostate gland; also found in erythrocytes, platelets, bone osteoclasts, and spleen.
• Historical and Current Uses:
  • Prostatic ACP was historically used to monitor metastatic prostate cancer, but has been entirely superseded by Prostate-Specific Antigen (PSA).
  • Forensic Investigation: Because seminal fluid contains exceptionally high concentrations of prostatic ACP, forensic laboratories utilize ACP spot tests and quantitative assays to verify the presence of semen in alleged sexual assault cases.
  • Tartrate-Resistant Acid Phosphatase (TRAP): Prostatic ACP is completely inhibited by L-tartrate ions, whereas osteoclastic ACP and the isoenzyme expressed by leukemic cells in Hairy Cell Leukemia are resistant to tartrate inhibition. Positive TRAP cytochemical staining or serum activity is a classical diagnostic hallmark of hairy cell leukemia.

Cholinesterases: Acetylcholinesterase vs Pseudocholinesterase

+-----------------------------------------------------------------------------------------+
|                    Comparison of True and Pseudocholinesterase                          |
+-----------------------------------------------------------------------------------------+
| Feature           True Cholinesterase (AChE)            Pseudocholinesterase (BCHE)     |
+-----------------------------------------------------------------------------------------+
| Alternative Name  Acetylcholinesterase                  Butyrylcholinesterase / Serum   |
|                                                         Cholinesterase                  |
|                                                                                         |
| Synthesis Site    Neurons, Neuromuscular Junctions,     Synthesized exclusively by      |
|                   Erythrocyte Membranes                 Hepatocytes; secreted into blood|
|                                                                                         |
| Natural Substrate Acetylcholine (neurotransmitter)      Butyrylcholine, Benzoylcholine, |
|                                                         Succinylcholine                 |
|                                                                                         |
| Clinical          Confirms paroxysmal nocturnal         Assesses synthetic liver        |
| Application       hemoglobinuria (PNH, decreased)       function; organophosphate       |
|                   and neural tube defects in amnio      toxicity; succinylcholine apnea |
+-----------------------------------------------------------------------------------------+

1. Assessment of Synthetic Hepatic Function:
   • Because Pseudocholinesterase (BCHE) is synthesized exclusively by hepatocytes, serum levels decline markedly in advanced hepatic cirrhosis, toxic liver failure, and severe protein malnutrition.
2. Organophosphate and Carbamate Pesticide Toxicity:
   • Organophosphate insecticides (malathion, parathion, chlorpyrifos) and chemical warfare nerve agents (sarin, VX) covalently phosphorylate the active-site serine hydroxyl group of cholinesterases, causing irreversible enzymatic inhibition.
   • Inactivation of acetylcholinesterase leads to massive accumulation of acetylcholine at post-ganglionic parasympathetic and neuromuscular junctions, producing lethal cholinergic crisis (SLUDGE syndrome: Salivation, Lacrimation, Urination, Defecation, Gastrointestinal cramps, Emesis; alongside muscle fasciculations and respiratory failure).
   • Measurement of serum Pseudocholinesterase activity is the primary diagnostic laboratory test used to confirm acute poisoning, evaluate exposure severity, and monitor antidote therapy (Atropine and Pralidoxime / 2-PAM).
3. Inherited Atypical Pseudocholinesterase & Succinylcholine Apnea:
   • Succinylcholine is a short-acting depolarizing muscle relaxant administered during surgical tracheal intubation. In normal patients, circulating plasma BCHE rapidly hydrolyzes succinylcholine within 3 to 5 minutes, allowing spontaneous respiration to resume.
   • Individuals harboring autosomal recessive mutations in the BCHE gene (the atypical $E_1^a$ allele, fluoride-resistant $E_1^f$ allele, or silent $E_1^s$ allele) produce an abnormal enzyme with severely diminished affinity for succinylcholine.
   • Clinical Outcome: Administration of standard succinylcholine doses causes prolonged neuromuscular paralysis and life-threatening apnea lasting 2 to 6+ hours, requiring prolonged mechanical ventilation.
   • The Dibucaine Inhibition Test:
     • Laboratory phenotyping utilizes Dibucaine, a local anesthetic that strongly inhibits normal wild-type pseudocholinesterase but does not inhibit the atypical enzyme.
     • Dibucaine Number (DN): The percentage of pseudocholinesterase activity inhibited by dibucaine under standardized conditions:
       • Normal Homozygotes ($E_1^u / E_1^u$): DN = 75% to 85% (Normal inhibition; susceptible to standard succinylcholine metabolism).
       • Heterozygotes ($E_1^u / E_1^a$): DN = 50% to 60% (Intermediate inhibition; slightly prolonged apnea).
       • Atypical Homozygotes ($E_1^a / E_1^a$): DN < 20% to 30% (Severe resistance to dibucaine; extreme succinylcholine apnea).

---

Diagnostic Biomarker Kinetics & Clinical Indication Matrix

+-----------------------------------------------------------------------------------------+
|               Diagnostic Biomarker Release Kinetics and Clinical Indications            |
+-----------------------------------------------------------------------------------------+
| Biomarker       Initial Rise  Peak Time     Return to Baseline  Primary Diagnostic Role |
+-----------------------------------------------------------------------------------------+
| Myoglobin       1 - 3 hours   6 - 9 hours   24 - 36 hours       Early rule-out of AMI   |
|                                                                 (High NPV; lacks spec.) |
|                                                                                         |
| hs-cTnI         3 - 6 hours   12 - 24 hours 7 - 10 days         Gold standard for AMI;  |
|                                                                 Myocardial necrosis     |
|                                                                                         |
| hs-cTnT         3 - 6 hours   12 - 24 hours 10 - 14 days        Gold standard for AMI;  |
|                                                                 Long diagnostic window  |
|                                                                                         |
| CK-MB Mass      3 - 6 hours   12 - 24 hours 48 - 72 hours       Detection of re-infarct;|
|                                                                 Relative Index > 2.5%   |
|                                                                                         |
| Serum Amylase   2 - 12 hours  24 hours      3 - 5 days          Acute pancreatitis;     |
|                                                                 ACCR > 5%               |
|                                                                                         |
| Serum Lipase    4 - 8 hours   24 hours      8 - 14 days         Preferred single test   |
|                                                                 for acute pancreatitis  |
|                                                                                         |
| LD-1 (Flipped)  12 - 24 hours 48 - 72 hours 10 - 14 days        Historical AMI marker;  |
|                                                                 Hemolytic anemia        |
+-----------------------------------------------------------------------------------------+

---

Two Enzymes the BOC Names Separately: ACE and Cholinesterase

Angiotensin-Converting Enzyme (ACE)

Angiotensin-converting enzyme appears by name in the BOC list of enzymes, and it is the one enzyme on that list with no cardiac, hepatic, or pancreatic role at all.

• Biochemistry: ACE is a zinc-dependent dipeptidyl carboxypeptidase that cleaves the C-terminal dipeptide from angiotensin I to generate the vasoconstrictor angiotensin II, and simultaneously inactivates the vasodilator bradykinin. It is anchored on pulmonary capillary endothelium and is also secreted by the epithelioid cells of granulomas.
• Principal clinical use: Serum ACE is elevated in a majority of patients with active sarcoidosis, where granuloma burden is the source. It is used to gauge disease activity and response to corticosteroid therapy rather than to make the diagnosis, because its specificity is poor: ACE also rises in Gaucher disease, hyperthyroidism, miliary tuberculosis, leprosy, histoplasmosis, hypersensitivity pneumonitis, primary biliary cholangitis, and uncontrolled diabetes. CSF ACE is measured when neurosarcoidosis is suspected.
• Method: Kinetic spectrophotometric assay using a synthetic tripeptide substrate such as hippuryl-histidyl-leucine, monitoring the released product.
• Interferences that make or break the result: Patients taking an ACE inhibitor (lisinopril, enalapril, captopril) have pharmacologically suppressed activity, so a normal or low result in a treated patient is uninterpretable — always check the medication list before reporting. Because ACE requires zinc, EDTA plasma is unacceptable: the chelator strips the metal cofactor and abolishes measured activity. Collect serum. A common insertion/deletion (I/D) polymorphism in the ACE gene shifts baseline activity substantially between individuals, which is another reason serial measurements in one patient outperform a single comparison to a population interval.

Cholinesterase (Pseudocholinesterase, Butyrylcholinesterase)

Hepatocyte-synthesized plasma cholinesterase has two examinable uses. It is a sensitive marker of hepatic synthetic function and of organophosphate/carbamate insecticide poisoning, in which activity falls sharply (erythrocyte acetylcholinesterase is the more specific marker of the toxic exposure, while plasma cholinesterase falls earlier). It is also the enzyme responsible for hydrolyzing succinylcholine; inherited atypical variants cause prolonged post-anesthetic apnea and are characterized with the dibucaine number, the percentage inhibition of the enzyme by dibucaine. Normal (usual) enzyme is inhibited roughly 75% to 85% (dibucaine number about 80), heterozygotes fall in an intermediate range near 40% to 60%, and the homozygous atypical phenotype is inhibited less than 20% to 30%. The dibucaine number reports enzyme quality, not quantity — it is a percentage, so it is unaffected by how much enzyme is present.